TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02563106
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04531475
Drug: X842
Normalized name: I'm afraid I don't have enough information to determine the full generic name for the drug abbreviation 'X842'. Drug abbreviations can vary and may not be standardized, so without more context about the specific clinical trial data, I cannot provide the full generic name. I apologize that I cannot give you a more definitive answer.
Approvals — FDA: no, EMA: no, PMDA: no
Description: X842 capsules
Study: NCT04531475
Drug: X842 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: X842 placebo-matching capsules
Study: NCT00799448
Drug: insulin NPH
Normalized name: insulin NPH human isophane
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00123162
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single vaginal dose of placebo and monitored for 4 hours.
Study: NCT01335256
Drug: BAY1000394
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY1000394 will be administered orally twice a day (bid) in a 4 week on / 2 week off schedule.
Study: NCT00749333
Drug: AZD8566
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution. Specific dose will be selected by the safety review committee
Study: NCT00749333
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 10ml oral solution.
Study: NCT03288974
Drug: POMALYST® (Pomalidomide)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The recommended starting dose of POMALYST is 4 mg once daily taken orally on Days 1 to 21 of repeated 28-day cycles. The recommended dose of dexamethasone is 40 mg orally once daily on Days 1, 8, 15 and 22 of each 28-day treatment cycle
Study: NCT00235235
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin 60 mg/m2 day 1 of every 21-day cycle
Study: NCT00235235
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 600 mg/m2 day 1 of every 21-day cycle
Study: NCT00235235
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1000 mg/m2 bid days 1-14 of every 21-day cycle
Study: NCT01498458
Drug: Pazopanib plus capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive pazopanib tablets once daily at a dose according to the allocated dose level:~* dose level I: 400 mg~* dose level II: 600 mg~* dose level III: 800 mg~In addition patients receive capecitabine at the same oral dose for all dose levels with 1600 mg/m2 on days 1 to 14 every 3 weeks.~Treatment will be given until disease progression or unacceptable toxicity of the study drug, or withdrawal of consent of the patient.~Six patients will be recruited in each dose level. If less than 2 out of 6 patients experience a DLT within the first 2 cycles (weeks 1 to 6), the next dose level is started. Once the MTD is established, additional 6 patients will be included into this dose level to further characterise the safety of the dose regimen.~If it is reported, that two patients had a DLT, all patients are informed about it and the dose level immediately reduced by one dose level.
Study: NCT01524224
Drug: LY2495655
Approvals — FDA: no, EMA: no, PMDA: no
Description: administered intravenously
Study: NCT01454609
Drug: 0.9% Normal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline
Study: NCT00296465
Drug: Pulsatile gonadotropin-releasing hormone (GnRH)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosages as specified, administered either subcutaneously (SC) or intraveneously (IV) as specified, via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks
Study: NCT00296465
Drug: Placebo Pulsatile GnRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered either intravenously or subcutaneously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks
Study: NCT04475588
Drug: Best supportive care (BSC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best supportive care (BSC) included drugs like antivirals, antibiotics, Hydroxychloroquine, oxygen therapy, LMWH, Steroids, Vitamins and Zinc
Study: NCT02296411
Drug: CHF 5259 12.5 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: comparison of CHF5259 versus placebo over 2 treatment periods of 6 weeks
Study: NCT03662542
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered.
Study: NCT00544258
Drug: PEP005
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01879410
Drug: UMEC/VI Inhalation Powder 62.5/25 mcg via NDPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: The drug is administered via NDPI as one inhalation once daily in the morning. NDPI has two strips, each containing 30 blisters of medication. The first strip has UMEC blended with lactose and magnesium stearate in the form of dry white powder with a dosage of 62.5 mcg per blister and the second strip has VI blended with lactose and magnesium stearate in the form of dry white powder with a dosage of 25 mcg per blister.
Study: NCT01879410
Drug: FSC Inhalation Powder 250/50 mcg via ACCUHALER/DISKUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: The drug is administered via ACCUHALER/DISKUS inhaler as one inhalation each morning and evening. The inhaler contains a single strip with 60 blisters of medication. The strip has 250 mcg of fluticasone propionate and 50 mcg of salmeterol per blister in the form of dry white powder.
Study: NCT01879410
Drug: Placebo DISKUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is administered via ACCUHALER/DISKUS inhaler as one inhalation each morning and evening. The inhaler contains 1 strip with 60 blisters of placebo in the form of dry white powder.
Study: NCT01879410
Drug: Placebo NDPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is administered via NDPI as one inhalation once daily in the morning. The inhaler contains 2 strips with 30 blisters of placebo per strip in the form of dry white powder.
Study: NCT01991158
Drug: High dose of methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate 3.0g/Kg, intravenous drip D1
Study: NCT00581776
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered by IV at 300 mg/m2, 6 doses spaced 12 hours apart on days 1-3 of each cycle, to start after completion of rituximab infusion
Study: NCT00581776
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given as a continuous infusion, 50 mg/m2 over 48 hours days 1-2 of each cycle, to start after completion of rituximab infusion.
Study: NCT02589782
Drug: Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB.
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01147861
Drug: GSK256073
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg in the AM and 5mg in the PM
Study: NCT01147861
Drug: GSK256073
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg in the AM
Study: NCT01147861
Drug: GSK256073
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg in the AM
Study: NCT01147861
Drug: GSK256073
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25mg in the AM and 25mg in the PM
Study: NCT03500133
Drug: Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low risk with complete early response after two cycles of ABVD chemotherapy schedule. Only one more ABVD course is delivered.
Study: NCT03500133
Drug: Low risk with partial remisssion after 4 cycles of ABVD chemotherapy schedule. Two ESHAP courses are delivered.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.
Study: NCT03500133
Drug: Intermediate risk with complete early response after two cycles of ABVD chemotherapy schedule. Three more ABVD courses are delivered.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate risk with complete early response after two cycles of ABVD chemotherapy schedule. Three more ABVD courses are delivered.
Study: NCT03500133
Drug: Intermediate risk with partial remission after two cycles of ABVD chemotherapy schedule. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate risk with partial remission after two cycles of ABVD chemotherapy schedule. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.
Study: NCT03500133
Drug: High risk with complete early response after 1 ABVD and 1 ESHAP courses. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.
Approvals — FDA: no, EMA: no, PMDA: no
Description: High risk with complete early response after 1 ABVD and 1 ESHAP courses. Four more chemotherapy courses are delivered alternating ESHAP and ABVD.
Study: NCT03500133
Drug: High risk with partial remission after 1 ABVD and 1 ESHAP courses. Six more chemotherapy courses are delivered alternating ESHAP and ABVD.
Approvals — FDA: no, EMA: no, PMDA: no
Description: High risk with partial remission after 1 ABVD and 1 ESHAP courses. Six more chemotherapy courses are delivered alternating ESHAP and ABVD.
Study: NCT03500133
Drug: Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low risk with partial remission at early response assessment after two cycles of ABVD chemotherpay schedule. Two ABVD courses are delivered.
Study: NCT01865279
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ascending single doses - 5 dose levels
Study: NCT01066104
Drug: Xolair placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: two to four weeks (dosage and frequency will be determined based on patient weight and IgE level)
Study: NCT01865279
Drug: isophane human insulin
Normalized name: insulin isophane, human
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of 0.4 IU/kg is administered to subjects with type 1 diabetes while a single dose of 0.6 IU/kg is administered to subjects with type 2 diabetes
Study: NCT00636909
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: preparative cytoreduction
Study: NCT00636909
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: immunosuppressive therapy
Study: NCT00904670
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo Oral Suspension 25mg/5mL; 20-60 mg/day
Study: NCT00904670
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo was a solution that was identical in taste and appearance to the Active drug that was used in this study.
Study: NCT03335904
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 50mg, BID
Study: NCT03456349
Drug: HTL0018318
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTL0018318
Study: NCT03456349
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00075855
Drug: therapeutic testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01264692
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral capsules matching ACT-280778
Study: NCT01878578
Drug: phenytoin
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hidantina® tablets containing 100 mg of phenytoin
Study: NCT01878578
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets containing matching placebo
Study: NCT02860234
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01110525
Drug: AZD1981
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4X100 mg per oral, twice daily for 28 days
Study: NCT01110525
Drug: Neovletta 21/28
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily with (21) or without (28) pause for bleeding.
Study: NCT01110525
Drug: Placebo AZD1981
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4X100 mg per oral, twice daily for 28 days
Study: NCT03028129
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet, without the active ingredient, similar in size, weight, color, taste and odor.
Study: NCT00683930
Drug: Mycophenolate Mofetil 2 g/Day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mycophenolate mofetil 500 mg tablets; 4 tablets twice daily for 52 weeks
Study: NCT00683930
Drug: Mycophenolate Mofetil (MMF) 3 g/Day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mycophenolate mofetil 500 mg tablets; 6 tablets twice daily for 52 weeks
Study: NCT00683930
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for MMF 2 g/day group: 4 tablets orally twice daily for 52 weeks; placebo for MMF 3 g/day group: 6 tablets orally twice daily for 52 weeks
Study: NCT00913887
Drug: Diclofenac Sodium 75 mg Tablets Under Fasting Conditions (Geneva Pharmaceutical)
Normalized name: diclofenac sodium 75 MG
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00913887
Drug: Diclofenac Sodium 75 mg Tablets Under Fed Conditions (Geneva Pharmaceutical)
Normalized name: diclofenac sodium 75 MG
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00913887
Drug: Voltaren 75 mg Tablets Under Fed Conditions (Geigy Pharmaceuticals)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02993822
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, once daily, oral
Study: NCT02094378
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered intranasally
Study: NCT01158820
Drug: Fentanyl load
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 µg bolus prior to bronchoscopy
Study: NCT01158820
Drug: Fentanyl demand
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 12.5 µg demand bolus at discretion of pulmonologist
Study: NCT01158820
Drug: Benadryl demand
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg bolus after 6th and 13th demand midazolam/fentanyl bolus
Study: NCT01849692
Drug: ESBA1008 solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection or infusion
Study: NCT01262560
Drug: Standard supportive care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receive standard supporting care for esophagitis-related pain as needed during concurrent chemotherapy and radiation treatment. The following regimen is recommended, but the local standard of care is permitted.~1. A compound containing viscous lidocaine and magnesium aluminum oxide (Maalox®);~2. Liquid or solid oxycodone, 5-10 mg, every 3 hours as needed.
Study: NCT01814046
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
Study: NCT02774993
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04382586
Drug: Supportive Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive care treatment was selected and administered as deemed appropriate by the study investigator
Study: NCT04382586
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match zanubrutinib
Study: NCT00648388
Drug: Pletal® Tablets 100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 single dose fasting
Study: NCT01039545
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac retard 75mg twice daily for 3 days, followed by fosfomycin 3g single dose on day 4 if deemed necessary
Study: NCT00555607
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone oral tablets (10 mg active ingredient per tablet) once a day at a dose of 0.5mg/kg bodyweight, during 14 days.
Study: NCT02789436
Drug: L. reuteri Prodentis® lozenges
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily, for 28 days
Study: NCT03192293
Drug: Metformin/Simvastatin/Fulvestrant
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 days Lead-in period: Metformin: 850mg (one tablet) twice a day Simvastatin: 20mg (one tablet) once every night~Once the doctor has deemed that patients have tolerated Simvastatin and Metformin well, patients will receive Fulvestrant at standard doses:~Cycle 1: 500mg (in the form of two injections, 1 in each buttock) at Day 1 and Day 15. Each cycle comprises of 28 consecutive days starting from Day 1.~Cycle 2 and beyond: 500mg at Day 1 of each 28-day cycle.~Tumour biopsy at 8 weeks. Every 8 weeks for the first 6 months, every 12 weeks thereafter:~Performance status evaluation Medical history and physical examination Clinical tumor measurement Review of treatment-related side-effects Blood taking for research purpose and routine blood tests Routine scans
Study: NCT01974206
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intramuscular injection
Study: NCT01063062
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: methotrexate as per standard of care in clinical practice.
Study: NCT02434549
Drug: Dysport®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injections in spastic muscle with regional muscle-related pain
Study: NCT02434549
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injections in spastic muscle with regional muscle-related pain
Study: NCT01762774
Drug: GSK2256294
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2256294 capsules will be administered as once daily as single dose 2 mg, 6 mg, 15 mg in Cohort 1 and 15 mg, 40 mg, 100 mg in Cohort 2. GSK2256294 capsules will be administered once or twice daily (cohorts 3 and 4) at the dose determined from the data from Cohort 1 and 2. GSK2256294 capsules will be available in 1, 5, 25 mg dose strength.
Study: NCT01762774
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be administered once daily (cohorts 1 and 2); and once or twice daily (cohorts 3 and 4).
Study: NCT00046293
Drug: Retrovase
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00335283
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one tablet bid
Study: NCT02707965
Drug: Oxcarbazepine (brand name vs generic drugs)
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
Study: NCT02707965
Drug: Phenytoin sodium (brand name vs generic drugs)
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
Study: NCT01951586
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered by intravenous infusion in participants with bone metastasis upon investigative site request for IV bone-targeted therapy.
Study: NCT01951586
Drug: Standard Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care chemotherapy consisting of pemetrexed or gemcitabine in combination with cisplatin or carboplatin administered according to local practice.
Study: NCT01951586
Drug: Placebo to Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered by intravenous infusion in participants with bone metastasis upon investigative site request for IV bone-targeted therapy.
Study: NCT02944708
Drug: Conventional chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03850093
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients received oral placebo 2 hrs preoperative
Study: NCT01111604
Drug: mFOLFOX-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin: 85 milligram per square meter (mg/m²) IV every 2 weeks (Q2W)~FA: 400 mg/m² IV Q2W (or LFA: 200 mg/m² Q2W if FA is unavailable).~5FU: 400 mg/m² bolus + 2400 mg/m² IV Q2W
Study: NCT01703091
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT03815695
Drug: FT-4202/Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive FT-4202/placebo and monitored for side effects while undergoing pharmacokinetics and pharmacodynamic studies
Study: NCT02384499
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% normal saline with fibrin glue injection to the anal sphincter of patients with fecal incontinence
Study: NCT04075513
Drug: Background therapy: Rapid acting insulin analogs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Route of administration: SC injection
Study: NCT03241940
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01003236
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 140 mg placebo tablets, 3 times per day for 3 months
Study: NCT02384473
Drug: Definity Suspension for Injection
Normalized name: Definity Suspension for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participant will receive contrast agent by intravenous administration
Study: NCT03312140
Drug: Choline Chloride
Normalized name: Choline Chloride
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03467893
Drug: Antacids
Normalized name: ANTACIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: number aof antacids treatment after PPI stop